Peer Review History

Original SubmissionMay 8, 2021
Decision Letter - Tai-Heng Chen, Editor

PONE-D-21-14243

De-novo nonconvulsive status epilepticus in adult medical inpatients without known epilepsy: analysis of mortality related factors and literature review.

PLOS ONE

Dear Dr. Novo-Veleiro,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 14 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tai-Heng Chen, M.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: No

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: No

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: In this study, Garcia-villafranca et al., reviewed 54 general medical patients over a three year period with a diagnosis of NCSE, and examined important factors that determined their outcome, finding that hyponatraemia and atrial fibrillation were significantly associated with mortality secondary to NCSE.

The study highlights a condition that should be considered promptly when diagnosing fluctuant conscious state, particularly in older patients. In addition, the literature review of over 600 papers initially is commendable. However there are some major flaws with the study that inevitably minimise the findings described, that I will discuss in turn.

Major points

1. It appears the initial analysis, the main factor associated with NCSE was antibiotic use (96%), so a crucial question is the indication, e.g. systemic infection such as UTI versus brain specific e.g. encephalitis. Other factors that were associated with NCSE were statistically addressed individually. However a number of the factors would seem related e.g. atrial fibrillation and presence of stroke, neuroleptic use and chronic psychiatric disturbance, etc. and should not be analysed separately. In addition other important factors such as glucose level, functional status (MRS), are not presented. It appears more patients had hyponatraemia compared with hypernatraemia, despite the subsequent mortality analysis. Indeed comparing just 3 patients (deceased) to 1 (survived) is quite underpowered. Other factors such as potassium, hypertension or hepatic levels were not subsequently included in the multivariate analysis for mortality, is there any reason for this? Finally no actual values for biochemistry across the group are given, just the threshold values chosen for definition; this is very important when relating factors such as hypernatraemia to NCSE and its mortality.

2. A significant number of patients with NCSE were on benzodiazepine therapy (57%) prior to diagnosis (page 16) – why was this?

Minor points

1. In addition (page 15) 10 patients (1/5 of total number) had previous seizures although the authors state that patients with previous epilepsy were not included.

2. In the methods (page 13) what ‘characteristic’ EEG findings were observed to diagnose NSCE. Were all the of the Salzburg criteria satisfied for all patients?

Reviewer #3: This paper is a manuscript which can be a good contribution to the literature for nonconvulsive status epilepticus (NCSE). Here are my suggestions:

1) How was seizure response characterized? Were the authors able to collect standardized data on EEG response? If not, please discuss and add as limitation.

2) The Discussion needs a greater depth to compare your data to the literature.

3) We await the development of your treatment guidelines.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer #2: In this study, Garcia-villafranca et al., reviewed 54 general medical patients over a three year period with a diagnosis of NCSE, and examined important factors that determined their outcome, finding that hyponatraemia and atrial fibrillation were significantly associated with mortality secondary to NCSE.

The study highlights a condition that should be considered promptly when diagnosing fluctuant conscious state, particularly in older patients. In addition, the literature review of over 600 papers initially is commendable. However there are some major flaws with the study that inevitably minimise the findings described, that I will discuss in turn.

Major points

Point 1.

It appears the initial analysis, the main factor associated with NCSE was antibiotic use (96%), so a crucial question is the indication, e.g. systemic infection such as UTI versus brain specific e.g. encephalitis. Other factors that were associated with NCSE were statistically addressed individually. However a number of the factors would seem related e.g. atrial fibrillation and presence of stroke, neuroleptic use and chronic psychiatric disturbance, etc. and should not be analysed separately. In addition other important factors such as glucose level, functional status (MRS), are not presented. It appears more patients had hyponatraemia compared with hypernatraemia, despite the subsequent mortality analysis. Indeed comparing just 3 patients (deceased) to 1 (survived) is quite underpowered. Other factors such as potassium, hypertension or hepatic levels were not subsequently included in the multivariate analysis for mortality, is there any reason for this? Finally no actual values for biochemistry across the group are given, just the threshold values chosen for definition; this is very important when relating factors such as hypernatraemia to NCSE and its mortality.

Authors responses to point 1: first of all, we would like to thank the reviewer for spending her/his time in reviewing our manuscript. Regarding to the first points we have made the following changes:

-Regarding antibiotic treatment we have specified the reason for these treatment in the new version of our manuscript, as follows: The reason for antibiotic treatment was respiratory tract infection in 41 cases, urinary tract infection in 9 cases and skin and soft tissue infection in 2 cases.

-With regard to the main factors included in the mortality analysis, we referred to chronic previous conditions, also in the case of atrial fibrillation, we have changed it in Table 1 to a better comprehension.

-We have added data regarding glucose levels, unfortunately, due to the retrospective nature of the analysis we cannot add reliable data regarding to functional status.

-We agree with the reviewer that the statistical power of our analysis is poor, due to the number of cases included in each group, we have added a paragraph in the limitations section remarking this fact. Nevertheless, we still consider our results as valuable, if we take into account the number of patients included in previous reports.

-The presence of potassium levels disorders or liver enzymes alterations were not included in the multivariate analysis because the univariate analysis showed no difference between groups, we have clarified this fact in the new version of our manuscript. We have added hyponatremia in Table 1 to a better comprehension.

-Regarding actual values, we have added the mean values for patients with ionic alterations following the reviewer´s suggestion.

Point 2.

A significant number of patients with NCSE were on benzodiazepine therapy (57%) prior to diagnosis (page 16) – why was this?

Authors responses to point 2: we have reviewed this information and the reason was the presence of sleep disorders in all cases, we have added this information in the new version of the manuscript.

Minor points

1. In addition (page 15) 10 patients (1/5 of total number) had previous seizures although the authors state that patients with previous epilepsy were not included.

Authors response: we thank the reviewer for this observation, we have clarified this fact in the manuscript. We excluded all patients with a formal diagnosis of epilepsy, this group of ten patients presented at least one isolated episode of previous seizures but had not been diagnosed with epilepsy.

2. In the methods (page 13) what ‘characteristic’ EEG findings were observed to diagnose NSCE. Were all the of the Salzburg criteria satisfied for all patients?

Authors response: we have confirmed with the neurophysiology department that all patients with a characteristic EEG satisfied the Salzburg criteria. We added this information in the new version of the manuscript.

Reviewer #3: This paper is a manuscript which can be a good contribution to the literature for nonconvulsive status epilepticus (NCSE). Here are my suggestions:

1) How was seizure response characterized? Were the authors able to collect standardized data on EEG response? If not, please discuss and add as limitation.

Authors response: first of all, we would like to thank the reviewer for spending her/his time in reviewing our manuscript. Unfortunately, a control EEG was only performed in 7 cases, we have added this data and also added a sentence regarding it in the limitations section, following the reviewer´s suggestion.

2) The Discussion needs a greater depth to compare your data to the literature.

Authors response: we thank the reviewer for this suggestion, following it we have added some information to the discussion section and made changes to improve it.

3) We await the development of your treatment guidelines.

Authors response: thank you for your words, we will be pleased to share them with you and all the scientific community in a new future paper.

Attachments
Attachment
Submitted filename: Response to reviewers.docx
Decision Letter - Emilio Russo, Editor

De-novo nonconvulsive status epilepticus in adult medical inpatients without known epilepsy: analysis of mortality related factors and literature review.

PONE-D-21-14243R1

Dear Dr. Novo-Veleiro,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Emilio Russo

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The authors have adequately addressed my previous comments, in particular inclusion criteria for the study and associated limitation of the relatively small cohort being analysed.

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

Formally Accepted
Acceptance Letter - Emilio Russo, Editor

PONE-D-21-14243R1

De-novo nonconvulsive status epilepticus in adult medical inpatients without known epilepsy: analysis of mortality related factors and literature review.

Dear Dr. Novo-Veleiro:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof Emilio Russo

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .